EP Patent

EP4321157B1 — New use of a combination of an angiotensin receptor blocker (arb) with a neutral endopeptidase inhibitor (nepi)

Assigned to Novartis AG · Expires 2024-10-23 · 2y expired

What this patent protects

Patent listed against null.

Drugs covered by this patent

Patent Metadata

Patent number: EP4321157B1
Jurisdiction: EP
Classification: —
Expires: 2024-10-23
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.